Animal Models of Polycystic Ovary Syndrome: A Review of Hormone-induced Rodent Models Focused on Hypothalamus-pituitary-ovary Axis and Neuropeptides

Overview

Journal Reprod Med Biol

Specialty Biology

Date 2019 Apr 19

PMID 30996678

Citations 40

Authors

Satoko Osuka

Natsuki Nakanishi

Tomohiko Murase

Tomoko Nakamura

Maki Goto

Akira Iwase

Fumitaka Kikkawa

Affiliations

Soon will be listed here.

Abstract

Background: Polycystic ovary syndrome (PCOS) is a common endocrine disorder among women of reproductive age and a major cause of infertility; however, the pathophysiology of this syndrome is not fully understood. This can be addressed using appropriate animal models of PCOS. In this review, we describe rodent models of hormone-induced PCOS that focus on the perturbation of the hypothalamic-pituitary-ovary (HPO) axis and abnormalities in neuropeptide levels.

Methods: Comparison of rodent models of hormone-induced PCOS.

Main Findings: The main method used to generate rodent models of PCOS was subcutaneous injection or implantation of androgens, estrogens, antiprogestin, or aromatase inhibitor. Androgens were administered to animals pre- or postnatally. Alterations in the levels of kisspeptin and related molecules have been reported in these models.

Conclusion: The most appropriate model for the research objective and hypothesis should be established. Dysregulation of the HPO axis followed by elevated serum luteinizing hormone levels, hyperandrogenism, and metabolic disturbance contribute to the complex etiology of PCOS. These phenotypes of the human disease are recapitulated in hormone-induced PCOS models. Thus, evidence from animal models can help to clarify the pathophysiology of PCOS.

Citing Articles

Prolonged administration of letrozole induces polycystic ovary syndrome leading to osteoporosis in rats: model development and validation studies.

Usmani Z, Ahmad S, Usmani Z, Mishra T, Najmi A, Amin S Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39976717 DOI: 10.1007/s00210-025-03906-5.

Therapeutic potential of L. extract on 7,12-dimethylbenz(a)anthracene (DMBA) -induced ovary cancer in Wistar rats: a biochemical, molecular and histopathological approach.

Zhang L, Yuan X, Peng Q Toxicol Res (Camb). 2025; 14(1):tfae235.

PMID: 39790360 PMC: 11707539. DOI: 10.1093/toxres/tfae235.

Melatonin increases superoxide dismutase 2 (SOD2) levels and improves rat ovarian graft function after transplantation.

Monteiro K, Damous L, Shiroma M, Termini L, Cipolla-Neto J, Simoes R J Ovarian Res. 2024; 17(1):204.

PMID: 39415169 PMC: 11481372. DOI: 10.1186/s13048-024-01512-2.

Superior metabolic improvement of polycystic ovary syndrome traits after GLP1-based multi-agonist therapy.

Sanchez-Garrido M, Serrano-Lopez V, Ruiz-Pino F, Vazquez M, Rodriguez-Martin A, Torres E Nat Commun. 2024; 15(1):8498.

PMID: 39353946 PMC: 11445520. DOI: 10.1038/s41467-024-52898-y.

Exploring blood pressure dynamics and oxidative stress markers in an animal model of polycystic ovary syndrome.

Oktanella Y, Ismiawati H, Zakaria H, Untari H Open Vet J. 2024; 14(8):1858-1865.

PMID: 39308709 PMC: 11415921. DOI: 10.5455/OVJ.2024.v14.i8.14.

References

Keller J, Mandala M, Casson P, Osol G . Endothelial dysfunction in a rat model of PCOS: evidence of increased vasoconstrictor prostanoid activity. Endocrinology. 2011; 152(12):4927-36. DOI: 10.1210/en.2011-1424. View

Caldwell A, Middleton L, Jimenez M, Desai R, McMahon A, Allan C . Characterization of reproductive, metabolic, and endocrine features of polycystic ovary syndrome in female hyperandrogenic mouse models. Endocrinology. 2014; 155(8):3146-59. DOI: 10.1210/en.2014-1196. View

Schulster A, Farookhi R, Brawer J . Polycystic ovarian condition in estradiol valerate-treated rats: spontaneous changes in characteristic endocrine features. Biol Reprod. 1984; 31(3):587-93. DOI: 10.1095/biolreprod31.3.587. View

Maliqueo M, Sun M, Johansson J, Benrick A, Labrie F, Svensson H . Continuous administration of a P450 aromatase inhibitor induces polycystic ovary syndrome with a metabolic and endocrine phenotype in female rats at adult age. Endocrinology. 2012; 154(1):434-45. DOI: 10.1210/en.2012-1693. View

Lehman M, Coolen L, Goodman R . Minireview: kisspeptin/neurokinin B/dynorphin (KNDy) cells of the arcuate nucleus: a central node in the control of gonadotropin-releasing hormone secretion. Endocrinology. 2010; 151(8):3479-89. PMC: 2940527. DOI: 10.1210/en.2010-0022. View

Osuka S, Nakanishi N, Murase T, Nakamura T, Goto M, Iwase A . Animal models of polycystic ovary syndrome: A review of hormone-induced rodent models focused on hypothalamus-pituitary-ovary axis and neuropeptides. Reprod Med Biol. 2019; 18(2):151-160. PMC: 6452010. DOI: 10.1002/rmb2.12262. View

Moran L, Misso M, Wild R, Norman R . Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010; 16(4):347-63. DOI: 10.1093/humupd/dmq001. View

Chaudhari N, Dawalbhakta M, Nampoothiri L . GnRH dysregulation in polycystic ovarian syndrome (PCOS) is a manifestation of an altered neurotransmitter profile. Reprod Biol Endocrinol. 2018; 16(1):37. PMC: 5896071. DOI: 10.1186/s12958-018-0354-x. View

Ahn T, Fergani C, Coolen L, Padmanabhan V, Lehman M . Prenatal testosterone excess decreases neurokinin 3 receptor immunoreactivity within the arcuate nucleus KNDy cell population. J Neuroendocrinol. 2014; 27(2):100-10. PMC: 4412353. DOI: 10.1111/jne.12244. View

10.

Dunaif A . Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997; 18(6):774-800. DOI: 10.1210/edrv.18.6.0318. View

11.

Shi D, Vine D . Animal models of polycystic ovary syndrome: a focused review of rodent models in relationship to clinical phenotypes and cardiometabolic risk. Fertil Steril. 2012; 98(1):185-93. DOI: 10.1016/j.fertnstert.2012.04.006. View

12.

Jang M, Lee M, Lee J, Bae C, Kim S, Ryu J . Oriental medicine Kyung-Ok-Ko prevents and alleviates dehydroepiandrosterone-induced polycystic ovarian syndrome in rats. PLoS One. 2014; 9(2):e87623. PMC: 3919730. DOI: 10.1371/journal.pone.0087623. View

13.

Seminara S, Messager S, Chatzidaki E, Thresher R, Acierno Jr J, Shagoury J . The GPR54 gene as a regulator of puberty. N Engl J Med. 2003; 349(17):1614-27. DOI: 10.1056/NEJMoa035322. View

14.

Silva M, Prescott M, Campbell R . Ontogeny and reversal of brain circuit abnormalities in a preclinical model of PCOS. JCI Insight. 2018; 3(7). PMC: 5928858. DOI: 10.1172/jci.insight.99405. View

15.

Osuka S, Iwase A, Nakahara T, Kondo M, Saito A, Bayasula . Kisspeptin in the Hypothalamus of 2 Rat Models of Polycystic Ovary Syndrome. Endocrinology. 2016; 158(2):367-377. DOI: 10.1210/en.2016-1333. View

16.

Ota H, Fukushima M, Maki M . Endocrinological and histological aspects of the process of polycystic ovary formation in the rat treated with testosterone propionate. Tohoku J Exp Med. 1983; 140(2):121-31. DOI: 10.1620/tjem.140.121. View

17.

Tsilchorozidou T, Overton C, Conway G . The pathophysiology of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2003; 60(1):1-17. DOI: 10.1046/j.1365-2265.2003.01842.x. View

18.

Brown R, Wilkinson D, Imran S, Caraty A, Wilkinson M . Hypothalamic kiss1 mRNA and kisspeptin immunoreactivity are reduced in a rat model of polycystic ovary syndrome (PCOS). Brain Res. 2012; 1467:1-9. DOI: 10.1016/j.brainres.2012.05.049. View

19.

Wang D, Wang W, Liang Q, He X, Xia Y, Shen S . DHEA-induced ovarian hyperfibrosis is mediated by TGF-β signaling pathway. J Ovarian Res. 2018; 11(1):6. PMC: 5763573. DOI: 10.1186/s13048-017-0375-7. View

20.

Lakhani K, Yang W, Dooley A, El-Mahdi E, Sundaresan M, McLellan S . Aortic function is compromised in a rat model of polycystic ovary syndrome. Hum Reprod. 2005; 21(3):651-6. DOI: 10.1093/humrep/dei399. View